Research finds drug prices increased without adding new clinical benefits
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023. These increases led to $815 million incremental added costs for U.S. payers.
Related News Articles
Headline
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
The AHA Nov. 15 filed friend-of-the-court briefs in the U.S. Court of Appeals for the 5th Circuit in support of an earlier denial by the U.S. District Court…
Headline
Johnson & Johnson Nov. 12 filed a lawsuit against the Department of Health and Human Services and the Health Resources and Services Administration asking a…
Headline
The AHA Nov. 7 filed a friend-of-the-court brief in the U.S. District Court for the District of Kansas in defense of the state's law protecting against…
Headline
The National Academy for State Health Policy’s Hospital Cost Tool “misses the mark in many ways, and its use by payers, purchasers and policymakers could have…